JP6101341B2 - 置換ピリドピリミジン化合物およびｆｌｔ３阻害剤としてのこれらの使用 - Google Patents

置換ピリドピリミジン化合物およびｆｌｔ３阻害剤としてのこれらの使用 Download PDF

Info

Publication number
JP6101341B2
JP6101341B2 JP2015501823A JP2015501823A JP6101341B2 JP 6101341 B2 JP6101341 B2 JP 6101341B2 JP 2015501823 A JP2015501823 A JP 2015501823A JP 2015501823 A JP2015501823 A JP 2015501823A JP 6101341 B2 JP6101341 B2 JP 6101341B2
Authority
JP
Japan
Prior art keywords
amino
compound
disease
bromo
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015501823A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015510942A5 (enExample
JP2015510942A (ja
Inventor
ウ キム，ホン
ウ キム，ホン
イ，ヒ，キュ
ソン，ホ−ジュン
イ，ジェキュ
コ，ジョン，ソン
キム，ジュン−ホ
キム，セ，ウォン
イ，イン，ヨン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oscotec Inc
Original Assignee
Oscotec Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oscotec Inc filed Critical Oscotec Inc
Publication of JP2015510942A publication Critical patent/JP2015510942A/ja
Publication of JP2015510942A5 publication Critical patent/JP2015510942A5/ja
Application granted granted Critical
Publication of JP6101341B2 publication Critical patent/JP6101341B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/305—Mercury compounds
    • A61K31/31—Mercury compounds containing nitrogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2015501823A 2012-03-22 2013-03-15 置換ピリドピリミジン化合物およびｆｌｔ３阻害剤としてのこれらの使用 Active JP6101341B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261614274P 2012-03-22 2012-03-22
US61/614,274 2012-03-22
PCT/US2013/032575 WO2013142382A1 (en) 2012-03-22 2013-03-15 Substituted pyridopyrimidine compounds and their use as flt3 inhibitors

Publications (3)

Publication Number Publication Date
JP2015510942A JP2015510942A (ja) 2015-04-13
JP2015510942A5 JP2015510942A5 (enExample) 2016-05-12
JP6101341B2 true JP6101341B2 (ja) 2017-03-22

Family

ID=49223277

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015501823A Active JP6101341B2 (ja) 2012-03-22 2013-03-15 置換ピリドピリミジン化合物およびｆｌｔ３阻害剤としてのこれらの使用

Country Status (21)

Country Link
US (1) US8877763B2 (enExample)
EP (1) EP2828259B1 (enExample)
JP (1) JP6101341B2 (enExample)
KR (1) KR102011770B1 (enExample)
CN (1) CN104428298B (enExample)
AU (1) AU2013235344B2 (enExample)
BR (1) BR112014023460B1 (enExample)
CA (1) CA2868156C (enExample)
CL (1) CL2014002505A1 (enExample)
EA (1) EA031267B1 (enExample)
ES (1) ES2694223T3 (enExample)
IL (1) IL234802B (enExample)
IN (1) IN2014MN02082A (enExample)
MX (1) MX360912B (enExample)
MY (1) MY184858A (enExample)
NZ (1) NZ700283A (enExample)
PL (1) PL2828259T3 (enExample)
SG (1) SG11201405942RA (enExample)
TR (1) TR201816480T4 (enExample)
WO (1) WO2013142382A1 (enExample)
ZA (1) ZA201407588B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102228034B1 (ko) * 2013-10-21 2021-03-16 제노스코 치환된 피리미딘 화합물 및 syk 억제제로서의 이의 용도
ES2747249T3 (es) * 2014-07-17 2020-03-10 Sunshine Lake Pharma Co Ltd Derivados de 1-(5-(terc-butil)isoxazol-3-il)-3-(4-((fenil)etinil)fenil)urea y compuestos relacionados como inhibidores de FLT3 para el tratamiento de cáncer
KR20160035411A (ko) * 2014-09-23 2016-03-31 주식회사 오스코텍 LRRK2 (Leucine Rich Repeat Kinase 2) 키나제 억제제로서의 피리도피리미딘 유도체 화합물
KR20170087913A (ko) * 2014-11-17 2017-07-31 로드아일랜드하스피틀 나노물질, 조성물, 합성, 및 어셈블리
BR112020026641A2 (pt) * 2018-06-27 2021-03-30 Oscotec Inc. Derivados de piridopirimidinona para o uso como inibidores de axl
KR20200022712A (ko) * 2018-08-23 2020-03-04 주식회사 오스코텍 8-브로모-2-(1-메틸피페리딘-4-일아미노)-4-(4-페녹시페닐아미노)피리도[4,3-d]피리미딘-5(6H)-온 염산염의 결정다형체 및 그 제조방법
KR102230721B1 (ko) * 2019-02-01 2021-03-22 주식회사 오스코텍 피리도피리미딘계 염산염을 포함하는 경구용 고형제제 및 이의 제조방법
BR112021018168B1 (pt) 2019-03-21 2023-11-28 Onxeo Composição farmacêutica, combinação e kit compreendendo uma molécula dbait e um inibidor de quinase para o tratamento de câncer
CN110327347B (zh) * 2019-08-16 2021-06-01 陕西科技大学 G-749在制备抗真菌药物中的应用
TWI759829B (zh) * 2019-08-23 2022-04-01 財團法人生物技術開發中心 作為第iii型受體酪胺酸激酶抑制劑之雜環吡唑衍生物
CA3159348A1 (en) 2019-11-08 2021-05-14 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
WO2023027966A1 (en) 2021-08-24 2023-03-02 Biomea Fusion, Inc. Pyrazine compounds as irreversible inhibitors of flt3
JP2025502748A (ja) 2021-12-30 2025-01-28 バイオメア フュージョン，インコーポレイテッド Ｆｌｔ３の阻害剤としてのピラジン化合物
EP4525873A1 (en) 2022-05-17 2025-03-26 Biomea Fusion, Inc. Flt3 combination therapy for cancer and compositions therefor
KR102440707B1 (ko) 2022-07-10 2022-09-05 이우미 공장 추천 시스템

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1433417A (zh) * 2000-01-27 2003-07-30 沃尼尔·朗伯公司 用于治疗神经变性疾病的吡啶并嘧啶酮衍生物
CA2420286A1 (en) * 2000-08-31 2002-03-07 F. Hoffmann-La Roche Ag 7-oxo pyridopyrimidines as inhibitors of a cellular proliferation
CN100358892C (zh) * 2000-08-31 2008-01-02 霍夫曼-拉罗奇有限公司 7-氧代吡啶并嘧啶
EP2025678A1 (en) * 2007-08-17 2009-02-18 Oncalis AG Pyrazolo[3,4-d]pyrimidine compounds and their use as modulators of protein kinase
TW200938542A (en) * 2008-02-01 2009-09-16 Irm Llc Compounds and compositions as kinase inhibitors
ES2432414T3 (es) * 2008-08-12 2013-12-03 Glaxosmithkline Llc Compuestos químicos
US8338481B2 (en) * 2009-01-28 2012-12-25 Ramot At Tel-Aviv University Ltd. Alkoxyalkyl S-prenylthiosalicylates for treatment of cancer
BR112012003661A2 (pt) * 2009-08-19 2017-04-25 Ambit Biosciences Corp "compostos de biarila e métodos de uso dos mesmos."
ES2658290T3 (es) * 2009-10-29 2018-03-09 Genosco Inhibidores de cinasa

Also Published As

Publication number Publication date
KR20140144709A (ko) 2014-12-19
SG11201405942RA (en) 2014-10-30
BR112014023460B1 (pt) 2020-09-01
ZA201407588B (en) 2015-11-25
EA201491747A1 (ru) 2015-10-30
WO2013142382A1 (en) 2013-09-26
US20130274274A1 (en) 2013-10-17
EA031267B1 (ru) 2018-12-28
AU2013235344B2 (en) 2017-03-16
TR201816480T4 (tr) 2018-11-21
ES2694223T3 (es) 2018-12-19
HK1208453A1 (en) 2016-03-04
JP2015510942A (ja) 2015-04-13
NZ700283A (en) 2016-08-26
MX2014011354A (es) 2014-12-05
MX360912B (es) 2018-11-22
CA2868156C (en) 2020-07-28
CA2868156A1 (en) 2013-09-26
EP2828259A4 (en) 2015-08-19
IN2014MN02082A (enExample) 2015-08-21
EP2828259A1 (en) 2015-01-28
CL2014002505A1 (es) 2015-10-02
PL2828259T3 (pl) 2019-02-28
AU2013235344A1 (en) 2014-10-09
US8877763B2 (en) 2014-11-04
CN104428298A (zh) 2015-03-18
EP2828259B1 (en) 2018-08-08
MY184858A (en) 2021-04-27
IL234802B (en) 2018-10-31
KR102011770B1 (ko) 2019-08-19
CN104428298B (zh) 2017-03-01

Similar Documents

Publication Publication Date Title
JP6101341B2 (ja) 置換ピリドピリミジン化合物およびｆｌｔ３阻害剤としてのこれらの使用
JP7181558B2 (ja) Ｅｇｆｒモジュレーターとしての置換２－アミノピリミジン誘導体
EP2498607B1 (en) Kinase inhibitors
US8404677B2 (en) Kinase inhibitors
JP7644023B2 (ja) ホスファチジルイノシトール３－キナーゼ阻害剤
TW201619150A (zh) 用於調節ｅｇｆｒ突變型激酶活性的化合物及組成物
TWI707855B (zh) 咪唑并嗒類化合物及其用途
HK1208453B (en) Substituted pyridopyrimidine compounds and their use as flt3 inhibitors
AU2010319382B2 (en) Kinase inhibitors
AU2010313240B2 (en) Kinase inhibitors
HK40097521A (zh) 三环类化合物及其用途
HK1175367A (en) Kinase inhibitors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160315

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160315

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20161007

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20161006

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20161220

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170106

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20161220

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20170131

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170224

R150 Certificate of patent or registration of utility model

Ref document number: 6101341

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250